Department of Oncology, University Hospital Zürich, Zürich, Switzerland.
Oncology. 2010;79(1-2):93-7. doi: 10.1159/000320604. Epub 2010 Nov 15.
To evaluate the impact of pegfilgrastim on engraftment, hospital stay and resources in patients with Hodgkin's and non-Hodgkin's lymphoma after conditioning with high-dose BEAM followed by autologous peripheral blood stem cell transplantation (APBSCT) compared with filgrastim.
We reviewed patient charts and our prospective transplantation database for clinical data from the post-transplant period. An integrated cost analysis, including the use of blood products and length of hospital stay, was also performed.
Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed. Thirty-four (68%) patients received single-dose pegfilgrastim (6 mg), and 20 (32%) patients received daily filgrastim (5 μg/kg) after APBSCT. No differences were observed regarding duration of neutropenia grade 4 (pegfilgrastim median 7 days/filgrastim median 8 days; p = 0.13), thrombocytopenia grade 4 (7/9.5 days, respectively; p = 0.21), fever (4.5/2 days; p = 0.057), intravenous antibiotic treatment (11/10 days; p = 0.75) or length of hospital stay (16.5/16 days; p = 0.27) between the groups. The use of pegfilgrastim resulted in 12% higher treatment-related costs when compared to filgrastim, without reaching statistical significance (p = 0.38).
Pegfilgrastim appears to be equivalent to filgrastim after high-dose BEAM followed by APBSCT in the treatment of lymphoma patients.
评估培非格司亭（pegfilgrastim）对比粒细胞集落刺激因子（filgrastim）对接受高剂量 BEAM 预处理后进行自体外周血造血干细胞移植（APBSCT）的霍奇金淋巴瘤和非霍奇金淋巴瘤患者的植入、住院时间和资源的影响。
我们回顾了患者病历和我们前瞻性移植数据库中移植后期间的临床数据。还进行了包括血液制品使用和住院时间的综合成本分析。
分析了 14 例霍奇金淋巴瘤（26%）和 40 例非霍奇金淋巴瘤（74%）患者。34 例（68%）患者在 APBSCT 后接受了单次 pegfilgrastim（6mg），20 例（32%）患者接受了每日 filgrastim（5μg/kg）。两组之间，第 4 级中性粒细胞减少症的持续时间（pegfilgrastim 中位数 7 天/filgrastim 中位数 8 天；p = 0.13）、第 4 级血小板减少症（分别为 7/9.5 天；p = 0.21）、发热（4.5/2 天；p = 0.057）、静脉内抗生素治疗（11/10 天；p = 0.75）或住院时间（16.5/16 天；p = 0.27）均无差异。与 filgrastim 相比，pegfilgrastim 的治疗相关成本增加了 12%，但无统计学意义（p = 0.38）。
在接受高剂量 BEAM 预处理后进行 APBSCT 治疗淋巴瘤患者时，培非格司亭似乎与 filgrastim 等效。
